QSI (Quantum-Si Incorporated) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $258,000, primarily from Platinum instruments and consumable kits.

Gross Profit: $74,000, resulting in a gross margin of 29%, driven by a higher proportion of consumables.

Operating Expenses: GAAP total operating expenses were $24.1 million, down from $25.6 million in Q1 2025. Adjusted operating expenses were $21.4 million, compared to $22.9 million in the prior year.

Cash Position: As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $190.4 million, expected to support operations into 2028.

Outlook for 2026: Anticipated total revenue of approximately $1 million and adjusted operating expenses of $98 million or less.

2Strategic Updates and Business Highlights

Proteus Development: Significant progress made, including successful sequencing on fully integrated Proteus instruments. The platform is expected to outperform the existing Platinum technology in terms of throughput and amino acid detection.

Market Preparation: Initiatives include a roadshow series to educate potential customers about Proteus, with early events showing strong attendance and interest.

Customer Engagement: Positive feedback from early access customers on the Proteus prototype, highlighting improvements in amino acid detection and read length compared to Platinum.

3Forward Guidance and Outlook

2026 Focus: Transition year with a focus on consumable utilization, modest new capital sales, and preparing for the Proteus launch.

Future Expectations: Management expects Proteus to drive long-term revenue growth and profitability. They anticipate a ramp-up in customer volume post-launch, although specific volume predictions remain uncertain.

4Bad News, Challenges, or Points of Concern

Revenue Generation: Current revenue is modest, reflecting a strategic decision to prioritize long-term adoption of Proteus over immediate revenue maximization.

Operating Expense Management: While expenses have decreased, the company is operating at a loss and must manage cash usage carefully as they approach the Proteus launch.

Market Timing: Customers are timing purchases closer to the availability of Proteus, which could delay revenue recognition.

5Notable Q&A Insights

Customer Experience with Proteus: Enhanced capabilities in amino acid detection and read lengths are expected to improve customer applications, particularly in identifying proteins and detecting post-translational modifications.

Volume Expectations: While Proteus is expected to increase usage among existing Platinum customers, exact volume increases are difficult to predict until the product is in the field.

Early Access Program: The selection process for early access sites will prioritize diverse market segments, including academic and commercial environments, with a handful of sites expected by summer.

Roadshow Feedback: Strong interest in Proteus, particularly for applications involving post-translational modifications, with no significant pushback on pricing noted so far. Overall, QSI is in a transitional phase, focusing on the development and market preparation for its new Proteus platform, while managing financial discipline amid modest current revenues.